2025 Key Updates in Science and Policy

Picture of Patrick Wang

Patrick Wang

Expert of Peptides | Ask me anything about Peptides | Sales Manager at AHB Lab
Cover

Table of Contents

From recent advances to challenges and ethical dilemmas that shape the scientific landscape, this article encompasses it all-from the intersection of science and policy. We cover all aspects, from AlphaFold3’s release of revolutionary AI code and the disturbing reproducibility crisis in biomedical research to the lapses in financial conflict disclosures and changes in public health and environmental policies. In addition, we discuss how research chimpanzees are being moved to sanctuaries and also a rather exciting cosmic find dealing with galaxies coming in pairs. Taken altogether, each of these news items provides quite the broad vision of challenging interactions among innovation, regulation, and society.

 

AlphaFold3 Code Released: A Breakthrough for Protein Prediction

In a long-awaited move, Google DeepMind just released the code for its super-advanced artificial intelligence software called AlphaFold3. Immediately, excitement erupted across the research community. AlphaFold3 was announced in Nature on May 8 for being able to predict protein structures and interactions with DNA, RNA, and other proteins in a way no other program has ever done-a major advance toward drug discovery and other scientific uses.

But that code was finally released more than six months after the presentation, to the frustration of many researchers. Critics said at that time that a lack of immediate access impeded reproducibility with only pseudocode and limited-use online portal available at that time. Now, on November 11, DeepMind released the complete code and model weights for non-commercial uses to allow the researchers to replicate the findings and build on them. The company also emphasized that at least a few groups had already reproduced AlphaFold3 from the pseudocode, itself demonstrating the reproducibility of the Nature paper.

 

Biomedical Studies Face Reproducibility Crisis

A recent global survey of biomedical research has exposed a disturbing trend: replication failures. Published in PLOS Biology, the survey of 1,630 biomedical scientists included 880 who said they had attempted to replicate another researcher’s work. Shockingly, 724 of those attempts failed, and nearly one-fourth of respondents admitted they couldn’t reproduce their own experiments.

This survey underlines a wider problem: 72% of those responding to the survey agreed there was a reproducibility crisis in the field. Scientists said that intense pressure to publish along with a lack of institutional and funding support are key drivers of irreproducible studies into journals. These findings really echo a 2016 survey in Nature that reported similar concerns across multiple scientific disciplines.

 

Financial Conflicts in Research Often Go Unflagged

A new study has exposed a surprising gap in the way financial conflicts of interest are disclosed in life sciences research. Published in PLOS ONE, the analysis examined 3,888 articles from 40 high-impact journals published in 2021 and 2022. The surprise conclusion: only 30% of the articles disclosed potential conflicts of interest, and just half of those disclosures were flagged in the National Institutes of Health’s PubMed database.

Since 2017, PubMed has had a field for conflict-of-interest statements, in hopes of making those disclosures more transparent. But the study found that many journals don’t use the feature very well. In an expanded analysis including 7,000 journals, just one-third submitted conflict-of-interest statements to PubMed – a factor some scientists consider important to the transparency and accountability of science publishing.

 

Public Health Under Scrutiny: RFK Jr.’s Potential Impact

As Donald Trump gets to work, one of his first moves is to embolden a vaccine skeptic: Robert F. Kennedy Jr. The public health world goes into high alert. This is an environmental lawyer whose past proposals have included banning fluoride from public water supplies and dismantling key departments of the FDA. Lawrence Gostin, a specialist in public health law, describes this as “the darkest day for public health and science in my lifetime.”

While the FDA and CDC enjoy a degree of independence from federal agencies, Kennedy’s presence has the potential to blow vaccine policy off course and undermine confidence in public health measures. Public health systems operating at the state level might struggle to hang onto evidence-based vaccination mandates. Experts caution that this erosion of trust in public health guidance is going to continue, with the consequence of complicating efforts to address the pressing health challenges even further.

 

Trump’s EPA Pick: Deregulation on the Horizon

President-elect Trump made a choice to lead the EPA that elicited sharp reactions. Now he’s nominated Lee Zeldin, the former New York congressman, to helm the agency. Zeldin has been known for his deregulatory position and recently promised to “unleash American businesses” with environmental protection rollbacks.

Environmental watchdog groups sound the alarm, pointing to Zeldin’s abysmal environmental voting record as their prime argument while in Congress. His nomination presages a rule of weakened critical climate policies and increased political interference in research programs at the EPA, says an advisory group; such actions warn of far-reaching ramifications on environmental health and safety.

 

Chimps Relocated to Sanctuary After Longstanding Debate

The U.S. National Institutes of Health said it will relocate 23 retired research chimpanzees from a New Mexico facility to the Chimp Haven sanctuary in Louisiana. The move is in line with major steps toward ending invasive biomedical research on chimpanzees, which NIH officially declared over in 2015.

The decision comes after years of controversy. In 2019, NIH ruled too many chimps were too old or ill to move-a decision that generated outrage among animal welfare activists. Questions about staffing at the current facility ultimately proved the catalyst for the agency’s change of heart. Chimp Haven expects the first arrivals to begin in early 2025 and plans other transfers for research chimps.

 

Stroke Researcher Takes Leave Amid Misconduct Allegations

Prominent Alzheimer’s and stroke researcher Berislav Zlokovic has been put on indefinite leave from the University of Southern California amid allegations of research misconduct. A year-long Science investigation found in many quarters a broad-spectrum concern about work overseen by Zlokovic, which has already caused a $30 million clinical trial to be canceled for a stroke drug candidate he helped develop.

Furthermore, the case required USC to refund approximately $2 million in funding allocated for the trial from the U.S. National Institutes of Health. The case sheds light on how challenging it is yet to maintain integrity in research, especially in high-stakes research, such as biomedical research.

 

Cosmic Discovery: Dual Galaxies Create Compound Lens

Astronomers have caught a rare cosmic alignment-two lined-up galaxies commanding a compound gravitational lens. This peculiar configuration distorts and magnifies light coming from a distant quasar, a super-massive black hole spewing intense radiation.

In a new work, using NASA’s James Webb Space Telescope and many other instruments, they studied six sharp images of the quasar, magnified up to 40 times. The zigzag path the light takes around the galaxies marks out a new tool for measuring the rate of expansion and history of the universe. The results are yet to be peer-reviewed and have been released as a preprint on arXiv. The study could have far-reaching implications for cosmology and the nature of dark matter.

 

Conclusion

This eclectic mix of stories about scientific and policy developments underlines the opportunities and challenges that face both researchers and policymakers in this week’s news. Tales of artificial intelligence advances, juxtaposed with ethical dilemmas and public health, raise a number of questions with regard to innovation, regulation, and societal consequence.

At AHB Lab, we’re dedicated to keeping you updated on these pivotal developments and their implications for our industry. Stay connected for more insights!

Leave a Reply

Your email address will not be published. Required fields are marked *

公司最新訊息

ICPPX® 透皮黑科技:喚醒自體修復的關節筋膜指南

真正喚醒身體自癒力的解決方案 面對關節僵硬、肩頸痠痛、足底筋膜炎,或是運動後的肌腱發炎,多數人是否已經習慣吞下止痛藥、敷上冰袋,或是定期到診所施打玻尿酸 ? 在生物醫學與抗衰老領域中,我們經常看到消費者陷入一個無止盡的迴圈:疼痛 ➡️ 抑制痛覺 ➡️ 暫時舒緩 ➡️ 再次發炎。這是因為傳統的醫療手段,往往只能帶來短暫的舒緩 。這篇文章將帶您從微觀的「生技醫學」視角,徹底揭開傳統保養的生理限制 ,並為品牌主與研發人員介紹一項能真正喚醒身體自癒力的新興胜肽(Peptides)解決方案 。   為何常規治療只是在「拖延時間」? 在探討胜肽科技之前,我們必須先釐清現有市場方案的盲點。傳統的關節與筋膜保養,很多時候只是在欺騙大腦與拖延時間 : 止痛藥與肌肉鬆弛劑(剪斷警報器):吞下非類固醇消炎止痛藥(NSAIDs),就像是房子著火了,你卻拿剪刀把狂響的「火災警報器」電線給剪斷 。藥物阻斷了痛覺神經,但深層組織裡的發炎大火不僅沒熄滅,甚至正越燒越旺,持續吃掉軟骨與肌腱 。  玻尿酸注射(漏水的水桶):人體內本來就存在「透明質酸酶」會自然代謝外來物 。施打外來玻尿酸,就像把水倒進一個底部有裂縫的水桶,水分終究會流失 。  冰敷與涼感貼布(延緩修復):低溫會強制收縮血管,等於在傷口外圍拉起封鎖線,把帶來氧氣與修復細胞的「救援部隊」擋在門外,反而延緩了真實的修復進度 。 

Read More
公司最新訊息

關節退化只能等著開刀?揭開常規止痛藥無效的兩大微觀真相與胜肽修復新趨勢

為什麼吃遍止痛藥,關節依然隱隱作痛? 當你吃盡各種止痛藥、試過無數次物理治療,關節與肩頸的疼痛卻依然如影隨形時,你或許會開始懷疑,難道是自己的身體真的「壞掉」了嗎 ? 大多數人面對關節僵硬與疼痛時,總以為這只是一種無可避免的「生理性磨損」 。面對這類困擾,我們習慣依賴常規的口服消炎藥或肌肉鬆弛劑來尋求微乎其微的短暫舒緩感 。然而,問題並不是你的修復能力消失了,而是你一直沒有揪出潛伏在身體深處的真正破壞者 。 今天,我們將帶你潛入微觀的細胞世界,揭開導致關節退化與筋膜反覆發炎、長久難以痊癒的兩大核心元凶 ,並探討為何「胜肽(Peptides)」這項先進的生物科技解決方案,正成為替代傳統低效消耗戰的未來趨勢。   揪出元凶:微觀世界裡的兩大破壞者 如果我們把你隱隱作痛的部位放在顯微鏡下觀察,你會看到一場令人毛骨悚然的細胞大火 。這正是導致你久病不癒的兩大核心痛點: 元凶一:細胞內的隱形野火(TNF-α 與 IL-1β) 當關節受損時,免疫系統會釋放出一群極度凶狠的促發炎因子,也就是惡名昭彰的 TNF-α 與 IL-1β 。 你可以把這兩個恐怖分子想像成極具腐蝕性的「體內硫酸」,它們正日以繼夜地侵襲、溶解你的關節軟骨與肌腱組織 。 這場大火會把負責製造軟骨與潤滑液的細胞「強制斷電」,逼迫軟骨細胞與纖維母細胞進入深度的休眠與罷工狀態 。只要細胞內的隱形野火一天不撲滅,軟骨自然無法得到重建

Read More
公司最新訊息

為什麼傳統消炎藥無法根治痠痛?揭秘「關健膠原肽療法」如何從源頭重啟肌腱筋膜修復力

當止痛藥成為一種無奈的妥協 現代人生活節奏緊湊,無論是長時間久坐辦公室盯著電腦,還是週末為了釋放壓力而瘋狂運動,你是否經常感到肩頸僵硬、手肘隱隱作痛,或是早晨剛下床踩地時,腳底傳來一陣刺痛 ?這些看似平常卻惱人的症狀,很可能正是「肌腱炎」或「筋膜炎」在向你發出警訊 。 以上的肌腱或是筋膜的警訊如 : 一、肌腱問題(例如:肌腱炎)的常見症狀 常見於手肘、肩膀、膝蓋、腳踝等部位: 🔹 1. 局部疼痛 活動時加劇(例如拿東西、走路、抬手)  靜止時可能減輕,但嚴重時會持續疼痛  🔹 2. 壓痛 用手按壓某條肌腱會明顯疼痛  🔹 3. 僵硬感 早上起床或久坐後特別明顯  活動後稍微改善  🔹 4. 無力或功能下降

Read More